Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Declines in estimated glomerular filtration rate (eGFR) of 30% or 40% and albuminuria have been proposed as surrogates for end-stage renal disease. However, changes in eGFR or albuminuria may not be valid under all circumstances as drugs always have effects on multiple renal risk markers. Changes in each of these other 'off-target' risk markers can alter renal risk (either beneficially or adversely), and can thereby confound the relationship between surrogates that are based on single risk markers and renal outcome. Risk algorithms that integrate the short-term drug effects on multiple risk markers to predict drug effects on hard renal outcomes may therefore be more accurate. The validity of these risk algorithms is currently investigated. SUMMARY: Given that drugs affect multiple renal risk markers, risk scores that integrate these effects are a promising alternative to using eGFR decline or albuminuria. Proper validation is required before these risk scores can be implemented.
|
Authors | Bauke Schievink, Peter G M Mol, Hiddo J Lambers Heerspink |
Journal | Current opinion in nephrology and hypertension
(Curr Opin Nephrol Hypertens)
Vol. 24
Issue 6
Pg. 492-7
(Nov 2015)
ISSN: 1473-6543 [Electronic] England |
PMID | 26335552
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Albuminuria
(metabolism)
- Animals
- Biomarkers
(analysis)
- Disease Progression
- Glomerular Filtration Rate
(physiology)
- Humans
- Kidney
(physiopathology)
- Renal Insufficiency, Chronic
(diagnosis, therapy)
|